Acta Haematologica最新文献_第8页

Acquired FX Deficiency in Multiple Myeloma without Concomitant Amyloidosis: A Rare Case Report. 无淀粉样变的多发性骨髓瘤获得性FX缺乏一例罕见病例报告。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2026-01-01 Epub Date: 2025-03-29 DOI: 10.1159/000545479

Roi Gat, Svetlana Trestman, Ilya Kirgner

引用次数: 0

A Bibliometric Analysis of Immunotherapy in Diffuse Large B-Cell Lymphoma from 2004 to 2024. 2004 - 2024年弥漫性大b细胞淋巴瘤免疫治疗的文献计量学分析。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2026-01-01 Epub Date: 2025-03-21 DOI: 10.1159/000545152

Yanling Wu, Xiaomin Chen, Yang Liu, Yu Zhao, Lixiu Luo, Qiuwen Mi, Xiaoying Wen, Chunlan Huang

{"title":"A Bibliometric Analysis of Immunotherapy in Diffuse Large B-Cell Lymphoma from 2004 to 2024.","authors":"Yanling Wu, Xiaomin Chen, Yang Liu, Yu Zhao, Lixiu Luo, Qiuwen Mi, Xiaoying Wen, Chunlan Huang","doi":"10.1159/000545152","DOIUrl":"10.1159/000545152","url":null,"abstract":"Introduction: Immunotherapy in DLBCL (diffuse large B-cell lymphoma) disease has become an active research area with great value and potential. However, bibliometric research in this area is still sparse. Through bibliometric analysis, we aimed to visualize the research hot spots and trends of immunotherapy in DLBCL disease to help understand the future development of basic and clinical research.Methods: The Web of Science Core Collection database was searched for articles and reviews related to the immunotherapy of DLBCL from 2004 to 2024. VOSviewers, CiteSpace, and the R package \"bibliometrix\" were used to conduct the bibliometric analysis.Results: A total of 662 articles were included. The number of immunotherapy treatments in DLBCL increased year by year. The publications came from 55 countries, led by the USA and the People's Republic of China, and 1,349 institutions, with the leading research institutions being The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Leukemia & Lymphoma is the journal with the most research, and Blood is the journal with the most co-citations. We identified 4,833 authors, among which Young and Ken H. had the most significant articles, while Neelapu S.S. had the largest number of co-citations. After analysis, the most common keyword is CAR T (CAR T cells: chimeric antigen receptor T-cell immunotherapy, a current and developing area of research.Conclusions: This is the first bibliometric study to comprehensively summarize research trends and advances in immunotherapy in DLBCL disease. This information will provide a reference for researchers and healthcare providers in immunotherapy research by clarifying recent research frontiers and hot spots such as CAR T cells, bispecific antibodies, and so on.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"168-186"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mind-Body Intervention in Chronic Lymphocytic Leukemia during the Watch-and-Wait Phase: Benefits Linked to Intervention Duration. 慢性淋巴细胞白血病在观察和等待阶段的身心干预：与干预时间有关的益处。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2026-01-01 Epub Date: 2025-03-24 DOI: 10.1159/000545407

Shirley Shapira, Barak Mizrahi, Naama Hirschberger, Noa Rabinowicz, Adi Zoref-Lorenz, Natalie Flaks-Manov

{"title":"Mind-Body Intervention in Chronic Lymphocytic Leukemia during the Watch-and-Wait Phase: Benefits Linked to Intervention Duration.","authors":"Shirley Shapira, Barak Mizrahi, Naama Hirschberger, Noa Rabinowicz, Adi Zoref-Lorenz, Natalie Flaks-Manov","doi":"10.1159/000545407","DOIUrl":"10.1159/000545407","url":null,"abstract":"Introduction: Mind-body interventions (MBIs) are therapeutic practices that target the interactions between cognitive, emotional, and physiological systems to influence health outcomes. Previously, we demonstrated that MBI prolonged lymphocyte doubling time and treatment-free survival (TFS) in treatment-naïve chronic lymphocytic leukemia (CLL) patients during the watch-and-wait phase. In this follow-up study, we investigated the long-term effects of MBI on TFS after the intervention ceased.Methods: Sixty participants from the initial study (34 who received intervention vs. 26 controls) were followed for an additional period of 20 months. TFS was assessed from the end of the intervention to the initiation of CLL therapy or death, using Kaplan-Meier analysis and the log-rank test.Results: By the end of the follow-up, 9 participants who previously received MBI and 6 controls initiated CLL treatment. No significant difference in TFS was found between the groups (log-rank test, p = 0.65).Conclusion: While MBI provided a clear advantage as long as it continued, our follow-up analysis suggests this effect diminishes after the intervention ends. Continuous or repeated MBI may be necessary for sustained improvements in TFS.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"198-201"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of Pre-Treatment Sarcopenia in Patients Newly Diagnosed with Lymphoma. 新诊断淋巴瘤患者治疗前肌肉减少症的患病率。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2026-01-01 Epub Date: 2025-04-05 DOI: 10.1159/000545358

Charlotte Nørregaard Grønset, Mary Jarden, Jan Christensen, Martin Hutchings, Anders Tolver, Charlotte Suetta

引用次数: 0

Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis. 流线- fms样酪氨酸激酶3突变急性髓系白血病的回顾性队列研究：首次复发或难治性诊断患者的真实世界治疗模式和临床结果。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2026-01-01 Epub Date: 2025-04-14 DOI: 10.1159/000545384

Amer M Zeidan, Rebekah Yu, Yuexi Wang, Ziyu Lan, David L Grinblatt, Dina Elsouda, James Spalding, Alana Block, Maelys Touya, Mark S Walker, Bhavik J Pandya

{"title":"Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.","authors":"Amer M Zeidan, Rebekah Yu, Yuexi Wang, Ziyu Lan, David L Grinblatt, Dina Elsouda, James Spalding, Alana Block, Maelys Touya, Mark S Walker, Bhavik J Pandya","doi":"10.1159/000545384","DOIUrl":"10.1159/000545384","url":null,"abstract":"Introduction: Recent advances in genomic research have expanded the treatment landscape for acute myeloid leukemia (AML). This study examined treatment patterns and clinical outcomes among relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-mutated AML patients.Methods: This retrospective longitudinal study included patients with confirmed AML diagnosis, FLT3 mutation, and 1st R/R event from 1/1/2015 to 1/31/2023 in the ConcertAI Oncology Dataset. Treatment patterns, FLT3 testing rates, real-world overall survival (rwOS), and real-world time to next treatment (rwTTNT) were studied.Results: Among the 336 treated patients, 50.6% received FLT3-tyrosine kinase inhibitors (FLT3-TKIs) as first treatment after R/R event, of which 51.8% received gilteritinib. High-intensity chemotherapy used as first treatment after R/R event decreased from 67.9% in 2015 to 20.0% in 2022, while FLT3-TKI utilization rose to 50% over the same period. Among the 246 patients tested for FLT3 at initial AML diagnosis, only 36% were retested at 1st R/R event. Median rwOS and rwTTNT among FLT3-TKI patients were 12.4 months and 2.9 months, respectively.Conclusion: This study reveals a trend toward increasing FLT3-TKI use and highlights the need for repeated FLT3 testing among R/R AML patients. Real-world evidence is vital in understanding R/R AML patient care amidst emerging therapies. .","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"125-136"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12112888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. 老年人新诊断费城染色体阴性急性淋巴细胞白血病的治疗。

IF 1.1 4区医学

Acta Haematologica Pub Date : 2026-01-01 Epub Date: 2025-06-10 DOI: 10.1159/000546381

Lourdes M Mendez, Daniel J DeAngelo, Marlise R Luskin

{"title":"Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.","authors":"Lourdes M Mendez, Daniel J DeAngelo, Marlise R Luskin","doi":"10.1159/000546381","DOIUrl":"10.1159/000546381","url":null,"abstract":"Background: Approximately half of newly diagnosed cases of acute lymphoblastic leukemia (ALL) occur in adults, but adults experience significantly higher rates of treatment failure and treatment-related mortality due to frequent presence of adverse disease biology and limited tolerability of conventional chemotherapy.Summary: Here, we discuss recent data from clinical trials investigating new approaches for initial treatment of Philadelphia chromosome-negative ALL in older adults. These trials investigate the incorporation of novel agents including the anti-CD22 antibody-drug conjugate inotuzumab, the CD19-CD3 bi-specific T-cell engager blinatumomab, and the BCL2 inhibitor venetoclax into treatment regimens, with some studies attenuating or omitting chemotherapy. We also discuss the role of allogeneic stem cell transplantation consolidation for this population and highlight the possibility of frontline CD19-directed chimeric antigen receptor T-cell therapy consolidation approaches for B-ALL. Finally, we discuss improved understanding of the genetic diversity of ALL in older adults including occurrence of ALL with TP53 mutation, ALL with myeloid gene mutations, and therapy-related ALL.Key message: Overall, we highlight progress for older adults with Ph-negative ALL with patients more frequently achieving a measurable residual disease-negative complete remission, but significant work remains to improve the safety of treatment as well as the depth and durability of treatment response.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"61-75"},"PeriodicalIF":1.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epiglottitis in Patients Treated for Acute Leukemia: Case Series and Systematic Review of the Literature. 急性白血病患者会厌炎的病例分析及文献系统回顾。

IF 2.8 4区医学

Acta Haematologica Pub Date : 2026-01-01 Epub Date: 2025-04-17 DOI: 10.1159/000545927

Adi Sherban, Avraham Frisch, Alon Rozenthal, Shira Buchrits, Baha Atamna, Daniel Ben-Ner, Sivan Eden, Ala Atamna, Yishai Ofran, Pia Raanani, Ofir Wolach

{"title":"Epiglottitis in Patients Treated for Acute Leukemia: Case Series and Systematic Review of the Literature.","authors":"Adi Sherban, Avraham Frisch, Alon Rozenthal, Shira Buchrits, Baha Atamna, Daniel Ben-Ner, Sivan Eden, Ala Atamna, Yishai Ofran, Pia Raanani, Ofir Wolach","doi":"10.1159/000545927","DOIUrl":"10.1159/000545927","url":null,"abstract":"Introduction: Acute epiglottitis is a medical emergency characterized by inflammation of supraglottic structures of the larynx and epiglottis. The clinical characteristics and course of this complication in acute leukemia (AL) are largely unknown. We present a case series and a systematic review of the literature of adult patients with AL and acute epiglottitis. Case Presentation: Four patients with acute myeloid leukemia (age 38-61 years) were diagnosed with acute epiglottitis during their intensive treatment course. One patient presented with epiglottitis at the end of induction, two at the end of consolidation therapy, and 1 patient presented with a later event. Three patients were in grade 4 neutropenia during infection onset (median aplasia duration to event 9 [range 4-14] days). All patients presented with neck pain and dysphagia and 2 patients also had dyspnea at presentation. Urgent invasive airway protection was required in 3 patients. Two patients died due to this complication, one suffered anoxic brain injury. A systematic literature review identified 8 additional cases of epiglottitis. Conclusion: Acute epiglottis is a rare but significant medical emergency with unique challenges in the setting of AL that is caused by atypical infectious pathogens. Early detection and a multidisciplinary therapeutic effort are crucial to improve patient outcome. .","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"328-337"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Favorable Rates of Cardiovascular Events with Stringent Cardiovascular Monitoring and a Lowered Dose of Ponatinib as Second-Line Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Failing or Intolerant to First-Line Second-Generation Tyrosine Kinase Inhibitor Treatment: Results of the Prospective PONS Trial. 慢性期慢性髓性白血病（CML-CP）患者对一线第二代酪氨酸激酶抑制剂（TKI）治疗失败或不耐受，采用严格的心血管监测和低剂量的波纳替尼作为二线治疗，心血管事件的有利发生率：前瞻性PONS试验的结果。

IF 2.8 4区医学

Acta Haematologica Pub Date : 2026-01-01 Epub Date: 2025-05-05 DOI: 10.1159/000545826

Philipp le Coutre, Andreas Burchert, Susanne Saußele, Thekla Schwarzer, Sebastian Stintzing, Uwe Pelzer, Lars Bullinger, Ahmet Elmaagacli, Christian Jehn, Frank Stegelmann, Andreas Hochhaus, Thomas Ernst, Joachim R Göthert

{"title":"Favorable Rates of Cardiovascular Events with Stringent Cardiovascular Monitoring and a Lowered Dose of Ponatinib as Second-Line Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Failing or Intolerant to First-Line Second-Generation Tyrosine Kinase Inhibitor Treatment: Results of the Prospective PONS Trial.","authors":"Philipp le Coutre, Andreas Burchert, Susanne Saußele, Thekla Schwarzer, Sebastian Stintzing, Uwe Pelzer, Lars Bullinger, Ahmet Elmaagacli, Christian Jehn, Frank Stegelmann, Andreas Hochhaus, Thomas Ernst, Joachim R Göthert","doi":"10.1159/000545826","DOIUrl":"10.1159/000545826","url":null,"abstract":"Introduction: In chronic myeloid leukemia patients, second-line treatment requires careful consideration of response and tolerability. As most patients need a more efficient tyrosine kinase inhibitor, ponatinib at a lowered dose should be evaluated in this setting.Methods: We studied a lowered dose of 30 mg ponatinib in second line in patients selected toward a low cardiovascular risk. In 22 screened patients, ponatinib was started in 18 patients previously treated with imatinib (n = 3), dasatinib (n = 9), or nilotinib (n = 6). Patients were frequently monitored for cardiovascular toxicities by testing of blood pressure, vital signs, ankle brachial index or duplex, oral glucose tolerance test, echocardiography, ECG, and fundoscopy. The study protocol allowed dose reductions in patients achieving MMR. Both previously resistant or intolerant patients were recruited.Results: No serious cardiovascular events were observed, and low-grade cardiovascular toxicity was negligible. By 12 months, 13 patients (92.9%) were in complete hematologic remission, 10 patients (55.6%) were in MMR, and 5 patients (27.8%) were in MR4. Most importantly, we demonstrated that thorough monitoring of cardiovascular risk is feasible.Conclusions: We demonstrated that a lowered dose of 30 mg ponatinib in selected patients can be maintained without serious cardiovascular complications, provided cardiovascular risk monitoring is performed. In our patient cohort, this approach resulted in favorable response rates.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"355-362"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review. 髓/淋巴肿瘤成纤维细胞生长因子受体1重排的鉴定和确认，以及现实世界中治疗模式和结果的表征：美国回顾性图表综述。

IF 2.8 4区医学

Acta Haematologica Pub Date : 2026-01-01 Epub Date: 2025-07-05 DOI: 10.1159/000546910

Shreekant Parasuraman, Kimberly Saverno, Kristin M Zimmerman Savill, Philomena Colucci

{"title":"Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review.","authors":"Shreekant Parasuraman, Kimberly Saverno, Kristin M Zimmerman Savill, Philomena Colucci","doi":"10.1159/000546910","DOIUrl":"10.1159/000546910","url":null,"abstract":"Introduction: Myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1) are rare, heterogenous, aggressive hematologic malignancies with FGFR1 rearrangements at the 8p11 locus. Pemigatinib, a potent selective inhibitor of FGFR1-3, is approved for relapsed/refractory MLN-FGFR1.Methods: This retrospective chart review included US adults with myeloproliferative neoplasm, unclassifiable (MPN-U), myelodysplastic syndrome (MDS)/MPN, post-MPN acute myelogenous leukemia, precursor T- or B-cell acute lymphoblastic leukemia/lymphoma, or mixed-phenotype acute leukemia with bone marrow biopsy and standard cytogenetic and/or molecular results. Probable cases of MLN-FGFR1 were identified and confirmed with cytogenetic or molecular testing results. Patient characteristics, diagnostic testing methods, treatments, and outcomes were abstracted.Results: Of 560 submitted cases, 51 (9.1%) were probable MLN-FGFR1, 33 (5.9%) of which were subsequently confirmed. Among patients with confirmed MLN-FGFR1, 8p11 translocation or FGFR1 rearrangements were detected with standard cytogenetics in 72.7%, break-apart fluorescence in situ hybridization in 66.7%, next-generation sequencing in 21.2%, and real-time polymerase chain reaction in 6.1%. All but 1 patient initiated treatment; 3 patients underwent allogenic stem-cell transplant.Conclusion: This study highlights the importance of cytogenetic and molecular evaluations in patients with chronic/blast phase hematologic malignancies to diagnose MLN-FGFR1. This is particularly important following US approval of pemigatinib for this hematologic malignancy. .","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"252-262"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Donor-Derived Clonal Haematopoiesis after Allogeneic Stem-Cell Transplantation: A Case Report. 病例报告：同种异体干细胞移植后供体来源的克隆造血。

IF 2.8 4区医学

Acta Haematologica Pub Date : 2026-01-01 Epub Date: 2025-09-18 DOI: 10.1159/000548473

Adrian Schwarzer, Christian Späth, Thomas Neumann, Jan Krönke, William H Krüger

引用次数: 0